Xspray employs a patent-protected technology platform in order to create a pipeline of anti-cancer products with clinically relevant improvements or value enhanced generic versions for patients. Xspray primarly develops protein kinase inhibitors (PKI) for targeted cancer treatments. PKI’s are the second largest segment within cancer drugs.
Xspray Pharma AB
Xspray uses advanced technology to develop improved and generic versions of already marketed drugs.